Conatus Pharmaceuticals Stock Price, News & Analysis (NASDAQ:CNAT)

$4.22 0.11 (2.68 %)
(As of 11/18/2017 11:13 AM ET)
Previous Close$4.22
Today's Range$4.33 - $4.09
52-Week Range$1.73 - $9.40
Volume288,033 shs
Average Volume313,987 shs
Market Capitalization$126.62 million
P/E RatioN/A
Dividend YieldN/A
Beta1.18

About Conatus Pharmaceuticals (NASDAQ:CNAT)

Conatus Pharmaceuticals logoConatus Pharmaceuticals Inc. is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease. Emricasan has the potential to interrupt the progression of liver disease and provide treatment options in multiple areas of liver disease. Emricasan is designed to slow or halt the progression of chronic liver disease caused by fibrosis and cirrhosis. Emricasan works by inhibiting caspases, which are a family of related enzymes that plays as modulators of critical cellular functions, including functions that result in apoptosis and inflammation.


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Sector: Medical
  • Symbol: NASDAQ:CNAT
  • CUSIP: N/A
  • Web: www.conatuspharma.com
Debt:
  • Debt-to-Equity Ratio: 0.41%
  • Current Ratio: 2.69%
  • Quick Ratio: 2.69%
Sales & Book Value:
  • Annual Sales: $800,000.00
  • Price / Sales: 158.25
  • Book Value: $1.04 per share
  • Price / Book: 4.06
Profitability:
  • Trailing EPS: ($0.81)
  • Net Income: ($29,730,000.00)
  • Net Margins: -80.98%
  • Return on Equity: -83.02%
  • Return on Assets: -25.04%
Misc:
  • Employees: 27
  • Outstanding Shares: 30,000,000
 

Frequently Asked Questions for Conatus Pharmaceuticals (NASDAQ:CNAT)

What is Conatus Pharmaceuticals' stock symbol?

Conatus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNAT."

How were Conatus Pharmaceuticals' earnings last quarter?

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced its earnings results on Wednesday, November, 1st. The biotechnology company reported ($0.13) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.05) by $0.08. The biotechnology company had revenue of $9.57 million for the quarter, compared to the consensus estimate of $16.06 million. Conatus Pharmaceuticals had a negative return on equity of 83.02% and a negative net margin of 80.98%. During the same period in the prior year, the business posted ($0.31) earnings per share. View Conatus Pharmaceuticals' Earnings History.

When will Conatus Pharmaceuticals make its next earnings announcement?

Conatus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March, 21st 2018. View Earnings Estimates for Conatus Pharmaceuticals.

Where is Conatus Pharmaceuticals' stock going? Where will Conatus Pharmaceuticals' stock price be in 2017?

6 Wall Street analysts have issued 1-year price objectives for Conatus Pharmaceuticals' shares. Their forecasts range from $10.00 to $26.00. On average, they expect Conatus Pharmaceuticals' stock price to reach $16.00 in the next year. View Analyst Ratings for Conatus Pharmaceuticals.

What are Wall Street analysts saying about Conatus Pharmaceuticals stock?

Here are some recent quotes from research analysts about Conatus Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Conatus presently has no approved product in its portfolio. The company’s lead candidate emricasan is in phase II development for treatment of chronic liver disease, including NASH fibrosis. We are positive on the company’s plans to initiate studies on emricasan, targeting different types of NASH patient populations as the market holds huge untapped potential. Though Conatus is progressing well with emricasan, it is still several years away from entering the market. Any development/regulatory setback on emricasan could hamper Conatus’ prospects. Notably, several companies are working on developing treatments for NASH which might make the market competitive for emricasan. The stock has underperformed the industry so far this year." (10/3/2017)
  • 2. Aegis analysts commented, "We believe that Novartis will likely exercise its option for worldwide exclusive rights to Emricasan. Potential Combination Products. Under the agreement, Novartis’ option includes the ability to develop products using either Emricasan as the sole active ingredient or in combination with other compounds in its pipeline (e.g., farnesoid X). The tiered royalties payable to Conatus for these potential combination products range from high-single digits to mid-teens and are subject to certain reductions." (3/16/2017)
  • 3. FBR & Co analysts commented, "We think the strong pairing formed when Conatus Pharmaceuticals signed an option, collaboration, and licensing agreement with Novartis (NVS) firmly de-risked the path for completing clinical development of CNAT's Phase III ready liver disease drug emricasan, which is the most clinically advanced drug candidate in liver cirrhosis. In particular, we look for CNAT to benefit from collaborative synergies with NVS's expertise in liver disease research, and its track record of success in drug development and commercialization. As it is now a key new program in NVS's pipeline of $1B-plus potential product candidates, we also think this deal validates the value of emricasan, with the $650M deal recognition of emricasan's potential application in liver diseases with different etiologies. Therefore, we reiterate our Outperform rating." (3/15/2017)

Are investors shorting Conatus Pharmaceuticals?

Conatus Pharmaceuticals saw a drop in short interest in the month of October. As of October 31st, there was short interest totalling 1,461,190 shares, a drop of 30.6% from the October 13th total of 2,104,172 shares. Based on an average daily trading volume, of 337,296 shares, the days-to-cover ratio is presently 4.3 days. Currently, 5.7% of the shares of the stock are short sold.

Who are some of Conatus Pharmaceuticals' key competitors?

Who are Conatus Pharmaceuticals' key executives?

Conatus Pharmaceuticals' management team includes the folowing people:

  • David F. Hale, Independent Chairman of the Board (Age 67)
  • Steven J. Mento Ph.D., President, Chief Executive Officer, Director (Age 65)
  • Keith W. Marshall, Chief Financial Officer, Principal Financial Officer, Chief Operating Officer, Executive Vice President
  • Alfred P. Spada Ph.D., Executive Vice President - Research & Development, Chief Scientific Officer (Age 57)
  • David T. Hagerty M.D., Executive Vice President, Clinical Development (Age 60)
  • Daniel L. Ripley, Senior Vice President - Business Development, Program and Alliance Management
  • Edward F. Smith III., Ph.D., Senior Vice President - Regulatory Affairs and Quality Assurance
  • Michelle L Vandertie, Acting Principal Accounting Officer (Age 53)
  • Daniel L. Kisner M.D., Additional Independent Director (Age 70)
  • Preston S. Klassen M.D., Additional Independent Director (Age 48)

Who owns Conatus Pharmaceuticals stock?

Conatus Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Bank of New York Mellon Corp (0.61%), Sterling Capital Management LLC (0.43%), Macquarie Group Ltd. (0.20%), New York State Common Retirement Fund (0.08%) and Wells Fargo & Company MN (0.06%). View Institutional Ownership Trends for Conatus Pharmaceuticals.

Who bought Conatus Pharmaceuticals stock? Who is buying Conatus Pharmaceuticals stock?

Conatus Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Sterling Capital Management LLC, Macquarie Group Ltd., Bank of New York Mellon Corp, Wells Fargo & Company MN and New York State Common Retirement Fund. View Insider Buying and Selling for Conatus Pharmaceuticals.

How do I buy Conatus Pharmaceuticals stock?

Shares of Conatus Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Conatus Pharmaceuticals' stock price today?

One share of Conatus Pharmaceuticals stock can currently be purchased for approximately $4.22.

How big of a company is Conatus Pharmaceuticals?

Conatus Pharmaceuticals has a market capitalization of $126.62 million and generates $800,000.00 in revenue each year. The biotechnology company earns ($29,730,000.00) in net income (profit) each year or ($0.81) on an earnings per share basis. Conatus Pharmaceuticals employs 27 workers across the globe.

How can I contact Conatus Pharmaceuticals?

Conatus Pharmaceuticals' mailing address is 16745 WEST BERNARDO DRIVE Suite 200, San Diego CA, 92127. The biotechnology company can be reached via phone at 858-376-2600 or via email at [email protected]


MarketBeat Community Rating for Conatus Pharmaceuticals (NASDAQ CNAT)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  226 (Vote Outperform)
Underperform Votes:  107 (Vote Underperform)
Total Votes:  333
MarketBeat's community ratings are surveys of what our community members think about Conatus Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Conatus Pharmaceuticals (NASDAQ:CNAT)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 6 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $16.00 (279.15% upside)

Consensus Price Target History for Conatus Pharmaceuticals (NASDAQ:CNAT)

Price Target History for Conatus Pharmaceuticals (NASDAQ:CNAT)

Analysts' Ratings History for Conatus Pharmaceuticals (NASDAQ:CNAT)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/2/2017HC WainwrightReiterated RatingBuy -> Buy$18.00 -> $17.00N/AView Rating Details
10/6/2017Seaport Global SecuritiesReiterated RatingBuy$16.00N/AView Rating Details
8/3/2017Stifel NicolausReiterated RatingBuy$10.00HighView Rating Details
5/15/2017AegisReiterated RatingBuy$11.00N/AView Rating Details
3/15/2017FBR & CoReiterated RatingOutperform$16.00HighView Rating Details
12/23/2016SunTrust Banks, Inc.Reiterated RatingBuy$17.00 -> $26.00N/AView Rating Details
11/9/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
10/4/2016Brean CapitalReiterated RatingBuy$7.00N/AView Rating Details
7/1/2016Roth CapitalInitiated CoverageBuy -> BuyN/AView Rating Details
(Data available from 11/19/2015 forward)

Earnings

Earnings History and Estimates Chart for Conatus Pharmaceuticals (NASDAQ:CNAT)

Earnings by Quarter for Conatus Pharmaceuticals (NASDAQ:CNAT)

Earnings History by Quarter for Conatus Pharmaceuticals (NASDAQ CNAT)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/21/2018        
11/1/2017Q3 2017($0.05)($0.13)$16.06 million$9.57 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.17)($0.19)$9.33 million$10.00 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.34)($0.14)$5.88 million$7.00 millionViewListenView Earnings Details
3/15/2017Q4 2016($0.32)($0.35)$0.80 millionViewN/AView Earnings Details
11/8/2016Q3($0.34)($0.31)ViewListenView Earnings Details
8/3/2016Q216($0.38)($0.30)ViewN/AView Earnings Details
5/5/2016Q116($0.35)($0.35)ViewN/AView Earnings Details
3/9/2016Q4($0.37)($0.30)ViewListenView Earnings Details
11/4/2015Q315($0.38)($0.31)ViewN/AView Earnings Details
8/5/2015Q215($0.34)($0.31)ViewN/AView Earnings Details
5/7/2015Q115($0.35)($0.38)ViewListenView Earnings Details
3/11/2015Q414($0.49)($0.34)ViewListenView Earnings Details
11/12/2014Q3($0.43)($0.42)ViewN/AView Earnings Details
8/13/2014Q214($0.39)($0.34)ViewListenView Earnings Details
5/13/2014Q1($0.34)($0.34)ViewN/AView Earnings Details
3/27/2014($0.27)($0.33)ViewN/AView Earnings Details
11/14/2013Q3($0.20)($0.28)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Conatus Pharmaceuticals (NASDAQ:CNAT)
2017 EPS Consensus Estimate: ($0.59)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.26)($0.01)($0.17)
Q2 20173($0.26)$0.00($0.17)
Q3 20173($0.26)($0.01)($0.11)
Q4 20174($0.26)($0.02)($0.14)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Conatus Pharmaceuticals (NASDAQ:CNAT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Conatus Pharmaceuticals (NASDAQ CNAT)

Insider Ownership Percentage: 13.90%
Institutional Ownership Percentage: 33.29%
Insider Trades by Quarter for Conatus Pharmaceuticals (NASDAQ:CNAT)
Institutional Ownership by Quarter for Conatus Pharmaceuticals (NASDAQ:CNAT)

Insider Trades by Quarter for Conatus Pharmaceuticals (NASDAQ CNAT)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/8/2015Daniel L KisnerDirectorBuy4,000$5.75$23,000.00View SEC Filing  
7/30/2013David F HaleDirectorBuy2,588$11.00$28,468.00View SEC Filing  
7/30/2013Luke EvninMajor ShareholderBuy165,265$11.00$1,817,915.00View SEC Filing  
7/30/2013Steven J MentoCEOBuy13,800$11.00$151,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Conatus Pharmaceuticals (NASDAQ CNAT)

Source:
DateHeadline
 Analysts Anticipate Conatus Pharmaceuticals Inc. (CNAT) Will Announce Earnings of -$0.17 Per Share Analysts Anticipate Conatus Pharmaceuticals Inc. (CNAT) Will Announce Earnings of -$0.17 Per Share
www.americanbankingnews.com - November 18 at 1:30 PM
Commit To Buy Conatus Pharmaceuticals At $2.50, Earn 9.4% Annualized Using OptionsCommit To Buy Conatus Pharmaceuticals At $2.50, Earn 9.4% Annualized Using Options
www.thestreet.com - November 16 at 12:58 PM
Short Interest in Conatus Pharmaceuticals Inc. (CNAT) Declines By 30.6%Short Interest in Conatus Pharmaceuticals Inc. (CNAT) Declines By 30.6%
www.americanbankingnews.com - November 14 at 1:02 AM
Short Interest Decreases By 30.6% For CNATShort Interest Decreases By 30.6% For CNAT
www.thestreet.com - November 11 at 5:13 PM
Conatus Pharmaceuticals Inc. (CNAT) Forecasted to Earn FY2017 Earnings of ($0.60) Per ShareConatus Pharmaceuticals Inc. (CNAT) Forecasted to Earn FY2017 Earnings of ($0.60) Per Share
www.americanbankingnews.com - November 9 at 8:30 AM
Conatus to Present at Stifel Healthcare ConferenceConatus to Present at Stifel Healthcare Conference
finance.yahoo.com - November 7 at 10:27 PM
Conatus Pharmaceuticals Inc. (CNAT) Forecasted to Earn FY2017 Earnings of ($0.47) Per ShareConatus Pharmaceuticals Inc. (CNAT) Forecasted to Earn FY2017 Earnings of ($0.47) Per Share
www.americanbankingnews.com - November 6 at 6:36 AM
FY2017 Earnings Forecast for Conatus Pharmaceuticals Inc. Issued By Seaport Global Securities (CNAT)FY2017 Earnings Forecast for Conatus Pharmaceuticals Inc. Issued By Seaport Global Securities (CNAT)
www.americanbankingnews.com - November 6 at 6:36 AM
Conatus (CNAT) Loss Wider Than Expected in Q3, Sales MissConatus (CNAT) Loss Wider Than Expected in Q3, Sales Miss
finance.yahoo.com - November 2 at 6:08 PM
Conatus Pharmaceuticals (CNAT) CEO Steve Mento on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaConatus Pharmaceuticals' (CNAT) CEO Steve Mento on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 2 at 4:19 AM
Conatus reports 3Q lossConatus reports 3Q loss
finance.yahoo.com - November 1 at 11:17 PM
Conatus Pharmaceuticals Inc. to Host Earnings CallConatus Pharmaceuticals Inc. to Host Earnings Call
finance.yahoo.com - November 1 at 6:13 PM
Conatus Pharmaceuticals Reports Third Quarter 2017 Financial Results and Program UpdatesConatus Pharmaceuticals Reports Third Quarter 2017 Financial Results and Program Updates
finance.yahoo.com - November 1 at 6:13 PM
Conatus Pharmaceuticals Inc. (CNAT) Issues Quarterly  Earnings Results, Beats Estimates By $0.02 EPSConatus Pharmaceuticals Inc. (CNAT) Issues Quarterly Earnings Results, Beats Estimates By $0.02 EPS
www.americanbankingnews.com - November 1 at 5:46 PM
Zacks: Analysts Expect Conatus Pharmaceuticals Inc. (CNAT) Will Announce Quarterly Sales of $16.06 MillionZacks: Analysts Expect Conatus Pharmaceuticals Inc. (CNAT) Will Announce Quarterly Sales of $16.06 Million
www.americanbankingnews.com - October 30 at 2:02 AM
Conatus Pharmaceuticals Inc (CNAT) Expected to Announce Earnings of -$0.05 Per ShareConatus Pharmaceuticals Inc (CNAT) Expected to Announce Earnings of -$0.05 Per Share
www.americanbankingnews.com - October 28 at 11:12 PM
Conatus Pharmaceuticals Inc. (CNAT) to Release Quarterly Earnings on WednesdayConatus Pharmaceuticals Inc. (CNAT) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - October 26 at 1:18 PM
Conatus Pharmaceuticals Inc. (CNAT) Given Average Rating of "Buy" by BrokeragesConatus Pharmaceuticals Inc. (CNAT) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - October 26 at 7:58 AM
Conatus Pharmaceuticals to Report Third Quarter 2017 Financial Results - GlobeNewswire (press release)Conatus Pharmaceuticals to Report Third Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - October 25 at 11:55 PM
Conatus Pharmaceuticals to Report Third Quarter 2017 Financial ResultsConatus Pharmaceuticals to Report Third Quarter 2017 Financial Results
feeds.benzinga.com - October 25 at 8:03 AM
Oversold Conditions For Conatus Pharmaceuticals (CNAT)Oversold Conditions For Conatus Pharmaceuticals (CNAT)
www.thestreet.com - October 24 at 7:42 PM
Conatus Entrusts Keith W. Marshall With Key Management Roles - NasdaqConatus Entrusts Keith W. Marshall With Key Management Roles - Nasdaq
www.nasdaq.com - October 21 at 4:54 AM
Conatus Pharmaceuticals (CNAT) Announces Poster Presentation ... - StreetInsider.comConatus Pharmaceuticals (CNAT) Announces Poster Presentation ... - StreetInsider.com
www.streetinsider.com - October 21 at 4:54 AM
Conatus Liver Disease Drug Gets Orphan Drug Tag in the EUConatus' Liver Disease Drug Gets Orphan Drug Tag in the EU
finance.yahoo.com - October 20 at 6:49 PM
Conatus Pharmaceuticals Announces Poster Presentation at AASLD Annual MeetingConatus Pharmaceuticals Announces Poster Presentation at AASLD Annual Meeting
finance.yahoo.com - October 20 at 6:49 PM
Conatus' Liver Disease Drug Gets Orphan Drug Tag in the EUConatus' Liver Disease Drug Gets Orphan Drug Tag in the EU
finance.yahoo.com - October 20 at 6:49 PM
Conatus Pharmaceuticals (CNAT) Granted Orphan Drug Designation for IDN-7314 for the Treatment of PSCConatus Pharmaceuticals (CNAT) Granted Orphan Drug Designation for IDN-7314 for the Treatment of PSC
www.streetinsider.com - October 19 at 5:51 PM
FDA Blesses 2nd CAR-T Cell Therapy, NVO One Step Away From Approval, AKTX SlumpsFDA Blesses 2nd CAR-T Cell Therapy, NVO One Step Away From Approval, AKTX Slumps
www.rttnews.com - October 19 at 4:45 AM
13 Stocks Moving In Wednesdays After-Hours Session - Benzinga13 Stocks Moving In Wednesday's After-Hours Session - Benzinga
www.benzinga.com - October 18 at 11:44 PM
Conatus Pharmaceuticals (CNAT) Granted Orphan Drug Designation for IDN-7314 for the Treatment of PSC - StreetInsider.comConatus Pharmaceuticals (CNAT) Granted Orphan Drug Designation for IDN-7314 for the Treatment of PSC - StreetInsider.com
www.streetinsider.com - October 18 at 11:44 PM
EMA Grants Conatus Orphan Drug Designation for IDN-7314 for the Treatment of PSCEMA Grants Conatus Orphan Drug Designation for IDN-7314 for the Treatment of PSC
finance.yahoo.com - October 18 at 6:44 PM
Technical Insights on Biotech Stocks -- Conatus Pharma, Immunomedics, INSYS Therapeutics, and InVivo TherapeuticsTechnical Insights on Biotech Stocks -- Conatus Pharma, Immunomedics, INSYS Therapeutics, and InVivo Therapeutics
www.bizjournals.com - October 17 at 6:05 PM
Non-Alcoholic Steatohepatitis 2017 Progress Update - NasdaqNon-Alcoholic Steatohepatitis 2017 Progress Update - Nasdaq
www.nasdaq.com - October 12 at 11:10 PM
$12.80 Million in Sales Expected for Conatus Pharmaceuticals Inc. (CNAT) This Quarter$12.80 Million in Sales Expected for Conatus Pharmaceuticals Inc. (CNAT) This Quarter
www.americanbankingnews.com - October 11 at 3:38 AM
 Analysts Anticipate Conatus Pharmaceuticals Inc. (CNAT) Will Announce Earnings of $0.02 Per Share Analysts Anticipate Conatus Pharmaceuticals Inc. (CNAT) Will Announce Earnings of $0.02 Per Share
www.americanbankingnews.com - October 9 at 6:26 PM
Conatus Pharmaceuticals Inc. (CNAT) Earns Buy Rating from Analysts at Seaport Global SecuritiesConatus Pharmaceuticals Inc. (CNAT) Earns Buy Rating from Analysts at Seaport Global Securities
www.americanbankingnews.com - October 7 at 2:58 PM
12 Biggest Mid-Day Gainers For Friday | Benzinga - Benzinga12 Biggest Mid-Day Gainers For Friday | Benzinga - Benzinga
www.benzinga.com - October 6 at 10:42 PM
Conatus Pharmaceuticals Inc (CNAT) Receives Average Recommendation of "Buy" from AnalystsConatus Pharmaceuticals Inc (CNAT) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - October 1 at 8:50 AM
Will Conatus Liver Disease Candidate Drive Long-Term Growth?Will Conatus Liver Disease Candidate Drive Long-Term Growth?
www.zacks.com - September 28 at 5:14 PM
Reviewing Conatus Pharmaceuticals (CNAT) and The CompetitionReviewing Conatus Pharmaceuticals (CNAT) and The Competition
www.americanbankingnews.com - September 23 at 4:20 PM
Conatus Pharmaceuticals Inc. (CNAT) Expected to Announce Quarterly Sales of $13.46 MillionConatus Pharmaceuticals Inc. (CNAT) Expected to Announce Quarterly Sales of $13.46 Million
www.americanbankingnews.com - September 23 at 12:00 PM
Hedge fund manager shuts firm to explore run for Connecticut governorHedge fund manager shuts firm to explore run for Connecticut governor
finance.yahoo.com - September 19 at 5:24 PM
Conatus (CNAT) Up 7% Since Earnings Report: Can It Continue? - NasdaqConatus (CNAT) Up 7% Since Earnings Report: Can It Continue? - Nasdaq
www.nasdaq.com - September 8 at 10:48 PM
Conatus (CNAT) Up 7% Since Earnings Report: Can It Continue?Conatus (CNAT) Up 7% Since Earnings Report: Can It Continue?
finance.yahoo.com - September 8 at 5:44 PM
Head-To-Head Comparison: Minerva Neurosciences (NERV) versus Conatus Pharmaceuticals (CNAT)Head-To-Head Comparison: Minerva Neurosciences (NERV) versus Conatus Pharmaceuticals (CNAT)
www.americanbankingnews.com - September 2 at 2:18 PM
Conatus Pharmaceuticals (CNAT) Appoints Keith Marshall as COO and CFOConatus Pharmaceuticals (CNAT) Appoints Keith Marshall as COO and CFO
www.streetinsider.com - September 1 at 5:35 PM
Conatus Pharmaceuticals (CNAT) Appoints Keith Marshall as COO ... - StreetInsider.comConatus Pharmaceuticals (CNAT) Appoints Keith Marshall as COO ... - StreetInsider.com
www.streetinsider.com - September 1 at 3:19 AM
Conatus Pharmaceuticals Appoints Keith W. Marshall as Executive Vice President, Chief Operating Officer and Chief Financial OfficerConatus Pharmaceuticals Appoints Keith W. Marshall as Executive Vice President, Chief Operating Officer and Chief Financial Officer
finance.yahoo.com - August 31 at 5:14 PM
Conatus to Present at Rodman & Renshaw Global Investment Conference - GlobeNewswire (press release)Conatus to Present at Rodman & Renshaw Global Investment Conference - GlobeNewswire (press release)
globenewswire.com - August 29 at 10:54 PM
Conatus to Present at Rodman & Renshaw Global Investment ConferenceConatus to Present at Rodman & Renshaw Global Investment Conference
finance.yahoo.com - August 29 at 5:41 PM

Social Media

Financials

Chart

Conatus Pharmaceuticals (NASDAQ CNAT) Chart for Sunday, November, 19, 2017
Loading chart…

This page was last updated on 11/19/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.